Study of Nivolumab in Combination With Gemcitabine/Cisplatin or Ipilimumab for Patients With Advanced Unresectable Biliary Tract Cancer

NCT03101566 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Biliary Tract Neoplasms

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

University of Michigan Rogel Cancer Center